Loading clinical trials...

COMPLETEDPhase 1NCT01126086

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

Primary Objective: \- To study effect of mild and moderate hepatic impairment on the pharmacokinetics of otamixaban. Secondary Objective: \- To assess the pharmacodynamic effects of otamixaban on s...

Lead sponsor: Sanofi•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616 · Hepatic Impairment (HI)

RECRUITINGPhase 1

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

NCT07023354 · Healthy, Hepatic Impairment

RECRUITINGPhase 1

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

NCT04271488 · Hepatic Impairment

RECRUITINGPhase 1

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

NCT05484206 · Hepatic Impairment, Cirrhosis

RECRUITINGPhase 1

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634 · Hepatic Impairment

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 8, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment25

Start dateMay 2010

Last updatedMay 8, 2014

Condition

Hepatic Impairment

Locations shown

Investigational Site Number 840003

Miami Gardens, Florida

Investigational Site Number 840001

Orlando, Florida

Investigational Site Number 840002

Knoxville, Tennessee

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2014Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Trial snapshot

Condition

Locations shown

For caregivers